The collaboration will leverage VUMC’s resource platform, including its comprehensive datasets hosted in Vanderbilt’s BioVU collection of DNA and plasma to enable data-driven insights and to accelerate discovery and development.

The researchers anticipate that their findings will inform personalized colorectal polyp surveillance, guide therapeutic prevention strategies, and ultimately reduce the burden of colorectal cancer nationwide.

Roden is internationally known for his contributions to understanding arrhythmias and to the field of pharmacogenomics.

He received the award for his pioneering work focusing on leveraging genetic information to enhance health care outcomes.

The analysis of genetic sequencing data from more than 34,000 people over a 17-year period by researchers at VUMC was published in eClinicalMedicine.

Even after comprehensive testing, about 30% of children with short stature — height below the third percentile on a growth chart — do not have a definitive diagnosis, leading to extended surveillance, testing and anxiety.

The research is another step toward development of targeted therapies aimed at reducing the incidence and medical burden of this common condition.